Cargando…
Population pharmacokinetics of polymyxin B: a systematic review
BACKGROUND: Polymyxin B (PMB) is a basic cyclic polypeptide antibiotic produced by Bacillus polymyxa, and is one of the last options for treating multi-drug-resistant negative bacterial infections in clinical practice. In recent years, many population pharmacokinetic studies of PMB have been conduct...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908148/ https://www.ncbi.nlm.nih.gov/pubmed/35280373 http://dx.doi.org/10.21037/atm-22-236 |
_version_ | 1784665813913960448 |
---|---|
author | Chen, Na Guo, Jianhao Xie, Jiao Xu, Mi Hao, Xing Ma, Kuifen Rao, Yuefeng |
author_facet | Chen, Na Guo, Jianhao Xie, Jiao Xu, Mi Hao, Xing Ma, Kuifen Rao, Yuefeng |
author_sort | Chen, Na |
collection | PubMed |
description | BACKGROUND: Polymyxin B (PMB) is a basic cyclic polypeptide antibiotic produced by Bacillus polymyxa, and is one of the last options for treating multi-drug-resistant negative bacterial infections in clinical practice. In recent years, many population pharmacokinetic studies of PMB have been conducted. This paper sought to comprehensively summarize the characteristics of population pharmacokinetic models of PMB and provide a theoretical basis for the individualized use of PMB. METHODS: In this review, we systematically searched the PubMed and Embase databases to find articles on population pharmacokinetic models published from database establishment to August 2021. RESULTS: A total of 10 studies were included in this review, including studies on various types of severe infections caused by multi-drug-resistant bacteria, hospital-acquired infections with fibrosis and other male and female populations, and a study of 2 continuous renal replacement therapy (CRRT) patients, aged 16–94 years, who received PMB doses of 10–360 mg/day (0.13–3.45 mg/kg/day), at an administration time of 0.5–6 hours. First-order linear elimination was used in all the studies; a 1-compartment model was used in 5 studies, and a 2-compartment model was used in 5 studies. The most common covariates were creatinine clearance (CrCL) and body weight. DISCUSSION: Although these studies included several covariates and total clearance (CL) was close, but the external validation of some models was poorly correlated between the actual and predicted value. Novel or potential covariates represent important directions for further study. |
format | Online Article Text |
id | pubmed-8908148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-89081482022-03-11 Population pharmacokinetics of polymyxin B: a systematic review Chen, Na Guo, Jianhao Xie, Jiao Xu, Mi Hao, Xing Ma, Kuifen Rao, Yuefeng Ann Transl Med Review Article BACKGROUND: Polymyxin B (PMB) is a basic cyclic polypeptide antibiotic produced by Bacillus polymyxa, and is one of the last options for treating multi-drug-resistant negative bacterial infections in clinical practice. In recent years, many population pharmacokinetic studies of PMB have been conducted. This paper sought to comprehensively summarize the characteristics of population pharmacokinetic models of PMB and provide a theoretical basis for the individualized use of PMB. METHODS: In this review, we systematically searched the PubMed and Embase databases to find articles on population pharmacokinetic models published from database establishment to August 2021. RESULTS: A total of 10 studies were included in this review, including studies on various types of severe infections caused by multi-drug-resistant bacteria, hospital-acquired infections with fibrosis and other male and female populations, and a study of 2 continuous renal replacement therapy (CRRT) patients, aged 16–94 years, who received PMB doses of 10–360 mg/day (0.13–3.45 mg/kg/day), at an administration time of 0.5–6 hours. First-order linear elimination was used in all the studies; a 1-compartment model was used in 5 studies, and a 2-compartment model was used in 5 studies. The most common covariates were creatinine clearance (CrCL) and body weight. DISCUSSION: Although these studies included several covariates and total clearance (CL) was close, but the external validation of some models was poorly correlated between the actual and predicted value. Novel or potential covariates represent important directions for further study. AME Publishing Company 2022-02 /pmc/articles/PMC8908148/ /pubmed/35280373 http://dx.doi.org/10.21037/atm-22-236 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article Chen, Na Guo, Jianhao Xie, Jiao Xu, Mi Hao, Xing Ma, Kuifen Rao, Yuefeng Population pharmacokinetics of polymyxin B: a systematic review |
title | Population pharmacokinetics of polymyxin B: a systematic review |
title_full | Population pharmacokinetics of polymyxin B: a systematic review |
title_fullStr | Population pharmacokinetics of polymyxin B: a systematic review |
title_full_unstemmed | Population pharmacokinetics of polymyxin B: a systematic review |
title_short | Population pharmacokinetics of polymyxin B: a systematic review |
title_sort | population pharmacokinetics of polymyxin b: a systematic review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908148/ https://www.ncbi.nlm.nih.gov/pubmed/35280373 http://dx.doi.org/10.21037/atm-22-236 |
work_keys_str_mv | AT chenna populationpharmacokineticsofpolymyxinbasystematicreview AT guojianhao populationpharmacokineticsofpolymyxinbasystematicreview AT xiejiao populationpharmacokineticsofpolymyxinbasystematicreview AT xumi populationpharmacokineticsofpolymyxinbasystematicreview AT haoxing populationpharmacokineticsofpolymyxinbasystematicreview AT makuifen populationpharmacokineticsofpolymyxinbasystematicreview AT raoyuefeng populationpharmacokineticsofpolymyxinbasystematicreview |